Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through two business units: Topical Products and Technology Group and the Immunology Group. The Topical Products and Technology Group business unit has four U.S. food and drug administration approved commercial products, a pipeline of topical and transdermal products focusing on pain and dermatology and four drug delivery platforms that support the creation of patented formulations that can deliver actives into the skin. The Immunology Group business unit has two commercial products, a development program for the treatment of allergic rhinitis and an immune system modulation platform that has the potential to support treatments for a broad range of immune system related disorders. Nuvo Pharmaceuticals was founded on August 22, 1983 and is headquartered in Mississauga, Canada.